FDA panel votes to lift peptide manufacturing ban amid safety data void
Newly appointed members, selected by Health and Human Services Secretary Robert F. Kennedy Jr., provide decisive votes despite absence of human safety or efficacy evidence.
A committee organised by the US Food and Drug Administration (FDA) has voted to endorse the removal of restrictions on the manufacture of peptides for human use, a decision that overturns a ban previously enforced by the Biden administration. The vote, which lifted limits on four specific peptides, was driven by newly appointed members hand-picked by Health and Human Services Secretary Robert F. Kennedy Jr., who has a personal interest in the substances.
The FDA advisory panel was sharply divided, with all pre-Kennedy members voting against lifting the restrictions. The newly appointed members, who were described as having obvious interests in the manufacture and sale of unapproved peptides, provided the decisive votes to overturn the ban. Decisions on three additional peptides are scheduled to be made on the following day.
Despite Mr Kennedy’s earlier claims that independent experts would rigorously evaluate substances using full clinical and pharmacological evidence, no safety or efficacy data was presented at the meeting. An FDA official stated to the committee that the agency had never approved anything that had not been tested in humans, highlighting the unusual nature of this recommendation.
Peptides are short chains of amino acids, typically 10 to 20 in length, differing from proteins which can consist of hundreds or thousands. While some peptides, such as insulin, are produced through targeted processing of proteins, understanding the downstream effects of many others often requires decades of research. Many candidates fail when moving from cell culture studies to intact animal models, yet the committee proceeded without such data.
The committee’s role is advisory, and the FDA retains the power to reject these recommendations. However, doing so would place FDA experts in direct conflict with Mr Kennedy, who has the authority to dismiss them. This dynamic creates a significant policy challenge as the agency navigates the intersection of regulatory standards and political appointment.
